|
1
|
Horn LC, Schnurrbusch U, Bilek K,
Hentschel B and Einenkel J: Risk of progression in complex and
atypical endometrial hyper-plasia: Clinicopathologic analysis in
cases with and without progestogen treatment. Int J Gynecol Cancer.
14:348–353. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ozdegirmenci O, Kayikcioglu F, Bozkurt U,
Akgul MA and Haberal A: Comparison of the efficacy of three
progestins in the treatment of simple endometrial hyperplasia
without atypia. Gynecol Obstet Invest. 72:10–14. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Daud S, Jalil SS, Griffin M and Ewies AA:
Endometrial hyperplasia-the dilemma of management remains: A
retrospective observational study of 280 women. Eur J Obstet
Gynecol Reprod Biol. 159:172–175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nieman KM, Romero IL, Van Houten B and
Lengyel E: Adipose tissue and adipocytes support tumorigenesis and
metastasis. Biochim Biophys Acta. 1831:1533–1541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sheppard D: Transforming growth factor
beta: A central modulator of pulmonary and airway inflammation and
fibrosis. Proc Am Thorac Soc. 3:413–417. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
ten Dijke P and Hill CS: New insights into
TGF-beta-Smad signalling. Trends Biochem Sci. 29:265–273. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bakin AV, Rinehart C, Tomlinson AK and
Arteaga CL: p38 mitogen-activated protein kinase is required for
TGFbeta-mediated fibroblastic transdifferentiation and cell
migration. J Cell Sci. 115:3193–3206. 2002.PubMed/NCBI
|
|
8
|
Gao Y, Li S and Li Q: Uterine epithelial
cell proliferation and endometrial hyperplasia: Evidence from a
mouse model. Mol Hum Reprod. 20:776–786. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wilusz JE, Sunwoo H and Spector DL: Long
noncoding RNAs: Functional surprises from the RNA world. Genes Dev.
23:1494–1504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eulalio A, Huntzinger E and Izaurralde E:
Getting to the root of miRNA-mediated gene silencing. Cell.
132:9–14. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang ZS, Wang J, Zhu BQ and Ge L: Long
noncoding RNA UCA1 promotes multiple myeloma cell growth by
targeting TGF-β. Eur Rev Med Pharmacol Sci. 22:1374–1379.
2018.PubMed/NCBI
|
|
14
|
Li D, Li H, Yang Y and Kang L: Long
noncoding RNA urothelial carcinoma-associated 1 promotes the
proliferation and metastasis of human lung tumor cells by
regulating MicroRNA-144. Oncol Res. 26:537–546. 2018. View Article : Google Scholar
|
|
15
|
Li T, Sun X and Jiang X: UCA1 involved in
the metformin-regulated bladder cancer cell proliferation and
glycolysis. Tumour Biol. 39:1010428317710823. 2017. View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Matias-Guiu X, Catasus L, Bussaglia E,
Lagarda H, Garcia A, Pons C, Muñoz J, Argüelles R, Machin P and
Prat J: Molecular pathology of endometrial hyperplasia and
carcinoma. Hum Pathol. 32:569–577. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pernicova I and Korbonits M:
Metformin-mode of action and clinical implications for diabetes and
cancer. Nat Rev Endocrinol. 10:143–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nestler JE: Metformin for the treatment of
the polycystic ovary syndrome. N Engl J Med. 358:47–54. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shao R, Li X, Feng Y, Lin JF and Billig H:
Direct effects of metformin in the endometrium: A hypothetical
mechanism for the treatment of women with PCOS and endometrial
carcinoma. J Exp Clin Cancer Res. 33:412014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen ZQ, Zhu HT and Lin JF: Reverse of
progestin-resistant atypical endometrial hyperplasia by metformin
and oral contraceptives. Obstet Gynecol. 112:465–467. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y
and Liao QP: Metformin promotes progesterone receptor expression
via inhibition of mammalian target of rapamycin (mTOR) in
endometrial cancer cells. J Steroid Biochem Mol Biol. 126:113–120.
2011. View Article : Google Scholar
|
|
23
|
Sharifzadeh F, Aminimoghaddam S, Kashanian
M, Fazaeli M and Sheikhansari N: A comparison between the effects
of metformin and megestrol on simple endometrial hyperplasia.
Gynecol Endocrinol. 33:152–155. 2017. View Article : Google Scholar
|
|
24
|
Wang T, Zhang J, Hu M, Zhang Y, Cui P, Li
X, Li J, Vestin E, Brännström M, Shao LR and Billig H: Differential
expression patterns of glycolytic enzymes and
mitochondria-dependent apoptosis in PCOS patients with endometrial
hyperplasia, an early hallmark of endometrial cancer, in vivo and
the impact of metformin in vitro. Int J Biol Sci. 15:714–725. 2019.
View Article : Google Scholar :
|
|
25
|
Shan W, Wang C, Zhang Z, Gu C, Ning C, Luo
X, Zhou Q and Chen X: Conservative therapy with metformin plus
megestrol acetate for endometrial atypical hyperplasia. J Gynecol
Oncol. 25:214–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sivalingam VN, Kitson S, McVey R, Roberts
C, Pemberton P, Gilmour K, Ali S, Renehan AG, Kitchener HC and
Crosbie EJ: Measuring the biological effect of presurgical
metformin treatment in endometrial cancer. Br J Cancer.
114:281–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ben Sahra I, Tanti JF and Bost F: The
combination of metformin and 2-deoxyglucose inhibits autophagy and
induces AMPK-dependent apoptosis in prostate cancer cells.
Autophagy. 6:670–671. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity in vivo.
Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X, Guo YR, Lin JF, Feng Y, Billig H and
Shao R: Combination of diane-35 and metformin to treat early
endometrial carcinoma in PCOS women with insulin resistance. J
Cancer. 5:173–181. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee TY, Martinez-Outschoorn UE, Schilder
RJ, Kim CH, Richard SD, Rosenblum NG and Johnson JM: Metformin as a
therapeutic target in endometrial cancers. Front Oncol. 8:3412018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tabrizi AD, Melli MS, Foroughi M,
Ghojazadeh M and Bidadi S: Antiproliferative effect of metformin on
the endometrium-a clinical trial. Asian Pac J Cancer Prev.
15:10067–10070. 2014. View Article : Google Scholar
|
|
33
|
Cantrell DA: Phosphoinositide 3-kinase
signalling pathways. J Cell Sci. 114:1439–1445. 2001.PubMed/NCBI
|
|
34
|
Santarpia L, Lippman SM and El-Naggar AK:
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Parekh TV, Gama P, Wen X, Demopoulos R,
Munger JS, Carcangiu ML, Reiss M and Gold LI: Transforming growth
factor beta signaling is disabled early in human endometrial
carcinogenesis concomitant with loss of growth inhibition. Cancer
Res. 62:2778–2790. 2002.PubMed/NCBI
|
|
36
|
Chandra V, Fatima I, Manohar M, Popli P,
Sirohi VK, Hussain MK, Hajela K, Sankhwar P and Dwivedi A:
Inhibitory effect of 2-(piper
idinoethoxyphenyl)-3-(4-hydroxyphenyl)-2H-benzo(b)pyran (K-1) on
human primary endometrial hyperplasial cells mediated via combined
suppression of Wnt/β-catenin signaling and PI3K/Akt survival
pathway. Cell Death Dis. 5:e13802014. View Article : Google Scholar
|
